Research programme: mental disorder therapeutics - Sunovion/PsychoGenics

Drug Profile

Research programme: mental disorder therapeutics - Sunovion/PsychoGenics

Alternative Names: SEP 360; SEP-378608

Latest Information Update: 24 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma; Sunovion Pharmaceuticals
  • Developer PsychoGenics; Sunovion Pharmaceuticals
  • Class Antipsychotics; Neuropsychotherapeutics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Mental disorders

Most Recent Events

  • 12 Jun 2017 Preclinical development is ongoing in USA
  • 12 Jun 2017 Sunovion files an IND application with the US FDA in USA for Mental disorders
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Mental-disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top